Stockreport
Regeneron and Telix Announce Strategic Radiopharma Collaboration
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody discovery/development platforms and oncology experience with Telix’s expertise in radiopharmaceutical development and manufacturing Telix to receive $40 million USD upfront for four initial programs with optionality to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion USD in development and commercial milestone payments plus low double-digit royalties TARRYTOWN, N.Y. and INDIANAPOLIS and MELBOURNE, Australia, April 13, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies. The collaboration combines Regeneron’s extensive biologics expertise, including bispe
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- NTLA Stock Rises 20% in 3 Months: Here's What You Should Know [Yahoo! Finance][Yahoo! Finance]
- Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What's Next [Yahoo! Finance][Yahoo! Finance]
- Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)[GlobeNewswire]
- Telix and Regeneron Announce Strategic Radiopharma Collaboration[PR Newswire]
- Regeneron Pharmaceuticals (REGN) had its price target raised by Morgan Stanley from $769.00 to $796.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- More
REGN
SEC Filings
SEC Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website
- More